soft tissue sarcoma (STS)
Conditions
Interventions
Group 1:Anthracycline-based drugs
Group 2:Ifosfamide-based
Group 3:Other chemotherapy options
Group 4:Combined molecular targeted therapy
Group 5:Combination immune checkpoint inhibitor therapy
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 years and above; 2. After anthracycline therapy progresses or is not suitable for anthracyclines, choose eribulin or eribulin combination therapy; 3. At least one target lesion according to RECIST1.1; 4. The included pathological subtypes include but are not limited to: undifferentiated sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, fibrosarcoma, angiosarcoma, etc.
Exclusion criteria
Exclusion criteria: 1. History of other malignant tumors, excluding basal cell carcinoma of the skin and carcinoma in situ of the cervix; 2. Participate in other clinical research cases; 3. According to CTCAE 5.0, there were adverse reactions greater than grade 2 before the use of eribulin, which was not suitable for intravenous chemotherapy, and had central nervous system metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR);Time to progression (TTP);Overall survival time (OS);Safey;Disease control rate (DCR); | — |
Countries
China
Contacts
Public ContactZhou Yuhong
Zhongshan Hospital, Fudan University
Outcome results
None listed